The protein galectin-1 has been identified as a possible therapeutic target for pancreatic cancer; new research has demonstrated that inhibiting this protein in mice with pancreatic cancer increased survival by 20%.
Pancreatic cancers dependent on signaling from a mutant Kras gene for their growth and progression in the laboratory are able to switch to Yap1, another oncogene, if Kras is blocked.
The addition of MM-398, a novel nanoliposome formulation of irinotecan, to standard treatment improves survival for metastatic pancreatic cancer patients who have already received gemcitabine.
A new vaccine triggered the growth of immune cell nodules within pancreatic tumors, reprogramming these intractable cancers and making them vulnerable to immune-based therapies.
Results of a phase I clinical trial of a vaccine therapy for pancreatic cancer indicate the treatment is well tolerated; in addition, it suggests that the vaccine stabilizes the disease for a period of time.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|